Addiction Patents (Class 514/810)
  • Patent number: 4918102
    Abstract: Prevention of or therapeutically curing the disease of alcoholism comprises supplementing the diet with biologically available chromium, such as naturally occurring chelated chromium.
    Type: Grant
    Filed: March 10, 1989
    Date of Patent: April 17, 1990
    Inventor: John P. Dobbins
  • Patent number: 4847281
    Abstract: The invention relates to the use of 1,2,3,9-tetrahydro-9-methyl-3-[(2-methyl-1H-imidazol-1-yl)methyl]-4H-carba zol-4-one and physiologically acceptable salts and solvates thereof in the relief or prevention of a withdrawal syndrome resulting from addiction to a drug or substance of abuse and/or for the suppression of dependence on drugs or substances of abuse.
    Type: Grant
    Filed: November 20, 1987
    Date of Patent: July 11, 1989
    Assignee: Glaxo Group Limited
    Inventor: Michael B. Tyers
  • Patent number: 4843071
    Abstract: Compositions and methods are disclosed for the treatment of obesity, depression, drug abuse, and narcolepsy. The compositions comprise a norepinephrine precursor such as L-tyrosine or L-phenylalanine in combination with a norepinephrine re-uptake inhibitor such as desipramine. In another embodiment of the invention, the compositions further comprise enzymatic cofactors for the biosynthesis of norepinephrine.
    Type: Grant
    Filed: December 5, 1986
    Date of Patent: June 27, 1989
    Assignee: Serotonin Industries of Charleston
    Inventor: Mark Hohenwarter
  • Patent number: 4834973
    Abstract: Immunoassays of psychoactive drugs including psychotomimetic drugs, narcotic drugs, and tetrahydrocannabinols and treatment methods based on the antigenic properties of protein conjugates of these drugs. These methods are based upon treating the psychoactive substances as haptens and utilizing their protein conjugates to produce antibodies to the psychoactive materials themselves. The immunoassay methods include both agglutination and agglutination-inhibition reactions. The treatment methods include treatment of both exogenous, administered drugs (such as cannabinols, LSD, heroin and morphine) and endogenous substances (such as N,N-Dimethyltryptamine and 5-Methoxy-N,N-Dimethyltryptamine), by active immunization and also passive immunization.
    Type: Grant
    Filed: October 30, 1986
    Date of Patent: May 30, 1989
    Inventor: Meir Strahilevitz
  • Patent number: 4816439
    Abstract: Human growth hormone is used for the treatment of individuals who are intoxicated with poisonous substances of the type which is degraded in the liver by microsomal enzymes, such as hexobarbiturates or alcohol.
    Type: Grant
    Filed: March 27, 1987
    Date of Patent: March 28, 1989
    Assignee: Nordiske Gentofte A/S
    Inventor: Karin D. Jorgensen
  • Patent number: 4786653
    Abstract: Treatment of the abuse of those addictive drugs whose apparent mode of operation includes first an enhancement of neurotransmitter activity and subsequently a reduction in that activity--and in accompanying pleasurable sensations--to such an extent that abusers thereof feel compelled to repeat the experience. Examples of abused drugs for which treatment is suitable are amphetamines, cocaine, meperidine, phencyclidine, and new "designer" drugs. The treatment is by daily dosage of phenelzine or equivalent phenylalkylhydrazine so as to effect a degree of monoamine oxidase inhibition incompatible with the abused drug during the period of treatment and for at least a couple weeks thereafter. Concurrent usage is productive of a broad range of dangerous and frightening reactions, described in graphic detail to all patients undergoing such treatment, and any breach of the prohibition confirms the necessity of remaining free of the abused drug throughout.
    Type: Grant
    Filed: August 24, 1987
    Date of Patent: November 22, 1988
    Inventor: Daniel H. Golwyn
  • Patent number: 4671959
    Abstract: Described is a method for reducing physiological and/or subjective reactivity to stress in humans being subjected to stress conditions. The method consists of administering to such humans an effective amount of a physiological and/or subjective stress reactivity-reducing substance selected from the group consisting of:(i) Nutmeg Oil;(ii) Mace Extract;(iii) Neroli Oil;(iv) Valerian Oil;(v) Myristicin;(vi) Isoelemicin; and(vii) Elemicin.Administration is through inhalation or transdermally using one or more of the above ingredients alone or in a suitable composition such as ethanol and/or a perfume composition, cologne or perfumed article (e.g., air freshener or deodorant stick). Also described is a method for detecting the reduction of physiological and/or subjective reactivity to stress in a human.
    Type: Grant
    Filed: May 2, 1986
    Date of Patent: June 9, 1987
    Assignees: Yale University, International Flavors & Fragrances Inc.
    Inventors: Craig B. Warren, Marina A. Munteanu, Gary E. Schwartz, Carlos Benaim, Henry G. Walter, Jr., Ronald S. Leight, Donald A. Withycombe, Braja D. Mookherjee, Robert W. Trenkle
  • Patent number: 4670463
    Abstract: Described is a method for reducing physiological and/or subjective reactivity to stress in humans being subjected to stress conditions. The method consists of administering to such humans an effective amount of a physiological and/or subjective stress reactivity-reducing substance selected from the group consisting of:(i) Nutmeg Oil;(ii) Mace Extract;(iii) Neroli Oil;(iv) Valerian Oil;(v) Myristicin;(vi) Isoelemicin; and(vii) Elemicin.Administration is through inhalation or transdermally using one or more of the above ingredients alone or in a suitable composition such as ethanol and/or a perfume composition, cologne or perfume article (e.g., air freshener or deodorant stick). Also described is a method for detecting the reduction of physiological and/or subjective reactivity to stress in a human.
    Type: Grant
    Filed: May 2, 1986
    Date of Patent: June 2, 1987
    Assignees: Yale University, International Flavors & Fragrances Inc.
    Inventors: Craig B. Warren, Marina A. Munteanu, Gary E. Schwartz, Carlos Benaim, Henry G. Walter, Jr., Ronald S. Leight, Donald A. Withycombe, Braja D. Mookherjee, Robert W. Trenkle
  • Patent number: 4670264
    Abstract: Described is a method for reducing physiological and/or subjective reactivity to stress in humans being subjected to stress conditions. The method consists of administering to such humans an effective amount of a physiological and/or subjective stress reactivity-reducing substance selected from the group consisting of:(i) Nutmeg Oil;(ii) Mace Extract;(iii) Neroli Oil;(iv) Valerian Oil;(v) Myristicin;(vi) Isoelemicin; and(vii) Elemicin.Administration is through inhalation or transdermally using one or more of the above ingredients alone or in a suitable composition such as ethanol and/or a perfume composition, cologne or perfumed article (e.g., air freshener or deodorant stick). Also described is a method for detecting the reduction of physiological and/or subjective reactivity to stress in a human.
    Type: Grant
    Filed: November 21, 1985
    Date of Patent: June 2, 1987
    Assignees: International Flavors & Fragrances Inc., Yale University
    Inventors: Craig B. Warren, Marina A. Munteanu, Gary E. Schwartz, Carlos Benaim, Henry G. Walter, Jr., Ronald S. Leight, Donald A. Withycombe, Braja D. Mookherjee, Robert W. Trenkle
  • Patent number: 4543212
    Abstract: Described herein are the composition, the characterization, the assay, the mode of action and the utility of a new alkaloid which may be isolated from a wide variety of natural materials by observing certain techniques and precautions herein set forth.
    Type: Grant
    Filed: September 9, 1983
    Date of Patent: September 24, 1985
    Assignee: Research Corporation of the University of Hawaii
    Inventor: Ralph M. Heinicke